Prognostic Value of CD74 and HLA-DR Expressions in Invasive Ductal Breast Cancer


Introduction: Despite the presence of many prognostic and predictive factors, overtreatment remains a major problem in patients with breast cancer. The aim of this study is to investigate the effects of CD74 and HLA-DR expressions on the prognosis of patients who have had a mastectomy for the treatment of breast cancer. Materials and Methods: A retrospective search of medical records was carried out for patients who had surgery for breast cancer at the Department of General Surgery, Akdeniz University School of Medicine, between March 1984 and November 1999. Patients with regular follow-up and necessary data for the study (i.e. patients’ demographics, pathology results, and treatment characteristics) were included in the study. Paraffin blocks of tumor specimens were re-examined with immunohistochemical methods in March 2010 to determine the extent of CD74 and HLA-DR expression and the level of tumor infiltrating lymphocyte (TILs). Results: The mean age and the median duration of follow-up for the 41 participants were 48.29 ± 11.86 years and 125 months (range 115 to 135 months), respectively. Disease-free survival (DFS) in CD74 negative subjects was better than in CD74 positive patients, but the difference was not statistically significant (p = 0.75). Similarly, HLA-DR negative and HLA-DR positive groups showed no statistically significant differences in terms of DFS (p = 0.81). Conclusion: There were positive but insignificant correlations with increased expression of CD74, decreased expression of HLA-DR, and TILs levels. Further studies involving larger sample sizes may provide more insight into these associations.

Share and Cite:

Yaprak, M. , Erdogan, G. , Aricic, G. , Ozcan, B. , Mesci, A. , Dınckan, A. , Erdogan, O. and Arici, C. (2015) Prognostic Value of CD74 and HLA-DR Expressions in Invasive Ductal Breast Cancer. Advances in Breast Cancer Research, 4, 71-76. doi: 10.4236/abcr.2015.43008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Ozmen, V. (2008) Breast Cancer in the World and Turkey. Journal of Breast Health, 4, 6-12.
[2] Aebi, S., Davidson, T., Gruber, G. and Cardoso, F. (2011) Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 22, vi12-vi24.
[3] Subramaniam, D.S. and Isaacs, C. (2005) Utilizing Prognostic and Predictive Factors in Breast Cancer. Current Treatment Options in Oncology, 6, 147-159.
[4] Weigel, M.T. and Dowsett, M. (2010) Current and Emerging Biomarkers in Breast Cancer: Prognosis and Prediction. Endocrine-Related Cancer, 17, R245-R262.
[5] Knauer, M., Cardoso, F., Wesseling, J., Bedard, P.L., Linn, S.C., Rutgers, E.J.T. and van’t Veer, L.J. (2010) Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-Gene Prognosis Signature. British Journal of Cancer, 103, 1788-1793.
[6] Jiang, Z., Xu, M., Savas, L., LeClair, P. and Banner, B.F. (1999) Invariant Chain Expression in Colon Neoplasms. Virchows Archiv, 435, 32-36.
[7] Ohtani, H. (2007) Focus on TILs: Prognostic Significance of Tumor Infiltrating Lymphocytes in Human Colorectal Cancer. Cancer Immunity, 7, 4.
[8] Nagata, S., Jin, Y.F., Yoshizato, K., Tomoeda, M., Song, M., Iizuka, N., et al. (2009) CD74 Is a Novel Prognostic Factor for Patients with Pancreatic Cancer Receiving Multimodal Theraphy. Annals of Surgical Oncology, 16, 2531-2538.
[9] Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Iwashige, H., Aridome, K., et al. (2001) Invariant Chain Expression in Gastric Cancer. Cancer Letters, 168, 87-91.
[10] Zheng, Y.X., Yang, M., Rong, T.T., Yuan, X.L., Ma, Y.H., Wang, Z.H., Shen, L.S. and Cui, L. (2012) CD74 and Macrophage Migration Inhibitory Factor as Therapeutic Targets in Gastric Cancer. World Journal of Gastroenterology, 18, 2253-2261.
[11] Lin, X., Wang, X., Capek, H.L., Simone, L.C., Tuli, A., Morris, C.R., et al. (2009) Effect of Invariant Chain on Major Histocompatibility Complex Class I Molecule Expression and Stability on Human Breast Tumor Cell Lines. Cancer Immunology, Immunotherapy, 58, 729-736.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.